Macular Degeneration Trial, Recruiting NCT06619405 Sponsor: Duke University Condition: Macular Degeneration
Back to Macular Degeneration

Macular Degeneration Trial, Recruiting

NCT06619405
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing and able to give their consent to participate
  • People who have been diagnosed with early or intermediate dry age-related macular degeneration, geographic atrophy, or who have healthy eyes (for the control group)
  • People who are at least 50 years of age

Who may not be able to join:

  • People who are unable or unwilling to give consent, or who are unable to read the consent forms (as the study involves reading-based tests)
  • People under 50 years of age
  • People who have dense cataracts in the eye(s) being studied that could affect vision test results
  • People who have glaucoma that requires treatment during the study, or who have visual field defects
  • People who have previously had laser treatment or surgery on the eye(s) being studied
  • People who have any other eye condition that would require long-term treatment or surgery during the study
  • People who have significant cloudiness or opacity in the cornea or eye that would prevent clear eye imaging and functional testing
  • People who have been diagnosed with nystagmus (involuntary eye movements) that would interfere with testing
  • People with high short-sightedness of -8 Diopters or more severe
  • People who have, in the opinion of the study doctor, any physical or mental health condition that could increase the risks of taking part or interfere with the study's tests and assessments

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Eleonora Lad, MD, PhD, Duke University

Phone: 919-684-4359

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
15 August 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Total number of participants with total ellipsoid zone (EZ) band attenuation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov